Zydus Wellness nod to Rs 1100 crore fund-raising

Published On 2020-08-28 04:45 GMT   |   Update On 2020-08-28 08:34 GMT

New Delhi: FMCG firm Zydus Wellness on Thursday said its board has approved plans to raise up to Rs 1,099.98 crore through a combination of issuance of shares to its promoter Zydus Family Trust on a preferential basis and other options.In a regulatory filing, Zydus Wellness said its board gave its approval "to issue, offer and allot equity shares on a preferential basis" to Zydus Family...

Login or Register to read the full article

New Delhi: FMCG firm Zydus Wellness on Thursday said its board has approved plans to raise up to Rs 1,099.98 crore through a combination of issuance of shares to its promoter Zydus Family Trust on a preferential basis and other options.

In a regulatory filing, Zydus Wellness said its board gave its approval "to issue, offer and allot equity shares on a preferential basis" to Zydus Family Trust. The board has accorded approval to raise Rs 349.98 crore through issuance of 21,30,000 shares at a price of Rs 1,643.10 per share.

Further, the board has also approved raising funds up to Rs 750 crore by issuing securities of the company, including equity shares (or equivalent instruments including but not limited to compulsorily convertible debentures, non-convertible debentures with warrants) through a private placement or qualified institutions placements (QIP) to qualified institutional buyers (QIBs) or a combination thereof.

The company said its board has decided to convene an extraordinary general meeting of the members of the company on September 19, 2020, to seek the approval of the members for the proposed fund raising activities.

As of quarter ended June 30, 2020, Zydus Family Trust held 4.29 per cent stake in Zydus Wellness.

Zydus Wellness offers brands such as Complan, Sugar Free, Nutralite and Everyuth.

Read also: Zydus Wellness Net Profit Rises 11 Per Cent At Rs 89 Crore In June Quarter

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News